Where energy and motion meet discovery
Valenthos Biophysics operates at the molecular decision layer of drug discovery, where binding events are interrogated, mechanisms are resolved, and uncertainty is converted into actionable insight.
Before biology. Before chemistry. Before scale. There is a moment where a binding event must be understood correctly. That is where we work.
We resolve molecular interactions beyond affinity, integrating kinetics, thermodynamics, and structural context to determine whether a signal is real, meaningful, and actionable.
We determine whether an interaction is real, how strong it is, and how it behaves over time by quantifying binding affinity (KD), association and dissociation kinetics (kon & koff), interaction quality and engagement. This establishes whether a molecular signal is robust, reproducible, and suitable for progression.
We resolve the thermodynamic drivers of binding by dissecting ΔG, ΔH, ΔS, stchoimetry and binding-coupled effects such as stabilization, folding, and conformational change. This defines why an interaction occurs and reveals the mechanistic basis required for rational optimization.
We integrate orthogonal biophysical data across multiple platforms to separate signal from artifact and resolve conflicting or ambiguous results. Outputs are structured as decision-focused analyses that define clear conclusions, prioritize hypotheses, and guide next l steps.
Drug discovery does not fail because experiments cannot be run. It fails because molecular signals are misunderstood, over-interpreted, or trusted when they should not be.
Valenthos Biophysics operates at the molecular decision layer, before biology, before chemistry, before scale, where binding events must be understood for what they truly are: signal or artifact, mechanism or coincidence, opportunity or dead end.
We do not generate data in isolation. We design experiments with intent, integrate orthogonal biophysical evidence, and translate complex molecular behavior into decision-ready understanding.
This is not a measurement workflow. It is a decision framework. By integrating binding kinetics, thermodynamics, and orthogonal validation, we resolve whether an observed interaction reflects true molecular engagement or experimental artifact. Every dataset is interpreted in context, enabling clear, defensible decisions on progression, optimization, or termination.
Rather than reporting isolated parameters, we define the mechanism behind the signal, how it forms, how stable it is, and whether it is actionable. This transforms complex biophysical data into decision-grade understanding.
Pascarella, T.W., Joseph, J.S.,Newman, J.M. et al. Precision by design: Surface plasmon resonance and theintegration of biophysics in fragment-based drug discovery. BiophysRev (2026). https://doi.org/10.1007/s12551-026-01429-8
Our scientific position is grounded not only in technical execution, but in a published framework for integrating SPR, thermodynamics, orthogonal biophysics, and structural biology to support fragment-based drug discovery decisions.
Pascarella, T.W., Joseph, J.S.,Newman, J.M. et al. Precision by design: Surface plasmon resonance and the integration of biophysics in fragment-based drug discovery. Biophys Rev (2026). https://doi.org/10.1007/s12551-026-01429-8
This work defines a practical framework for using SPR within integrated fragment discovery workflows, emphasizing rigorous experimental design, orthogonal validation, structural context, and stage-appropriate interpretation of weak molecular interactions.
Rather than treating SPR as an isolated readout, the paper argues that confident discovery decisions emerge from convergence across independent methods. In this model, the value of a signal is defined not only by detection, but by how rigorously it is interpreted in context.
Todd William Pascarella
Director of Biophysics Development
PascarellaTodd@Valenthosbio.com
Jason Michael Newman
Director of Operations
NewmanJason@Valenthosbio.com
Paulo Roberto Pascarella
Founder
Paulo@Valenthosbio.com
Valenthos Biophysics operates at the molecular decision layer of drug discovery.
To discuss a project, pilot study, or collaboration, reach out directly:
contact@Valenthosbio.com